Clinical evaluation of combination assay of serum tumor markers in non-small-cell lung cancer patients / 中华全科医师杂志

ABSTRACT

The pre-treatment serum levels of carbohydrate antigen 125 (CA125),cytokeratin 19 fragment 21-1 (CYFRA21-1),squamous carcinoma associated antigen (SCC-Ag),and tissue polypeptide antigen (TPA) were measured in 111 patients with primary non-small-cell lung cancer.And 103 benign lung disease cases and 97 healthy volunteers were also studied as controls.Enzyme linked immunosorbent assay (ELISA) was employed to detect the serum contents of SCC-Ag and TPA.The levels of CA125 and CYFRA21-1 were measured by electrochemical luminescence.The serum level of CYFRA21-1,SCC,TPA and CA125 in cancer patients were significantly higher than those of normal control and benign disease groups (P ＜ 0.01).The combined detection of tumor markers could significantly improve the sensitivity and specificity.And the levels of tumor markers were also correlated with the clinical stages and differentiation degrees.